EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Therapeutic Effects of Tamsulosin in Nightmare Disorder: A Randomized, Double Blind, Placebo-Controlled, Cross-Over, Pilot Study

Negin Naderifar, Elnaz Roohi, Ali Sharifi, Nemat Jaafari, Farshad Hashemian

Drug Research · 01.02.2024 · 74 (02) · 53-59

DOI: 10.1055/a-2226-3604 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Research, erschienen am 01.02.2024. Verfasst von Negin Naderifar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Dreams, Tamsulosin. Die Arbeit nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nightmare disorder is associated with functional impairment, distress, and low quality of life; however, studies on pharmacotherapy of this debilitating disorder yielded mixed results. Prazosin, a non-selective α1 blocker is reported to be effective in treatment of post-traumatic stress disorder-related nightmares. We aimed at investigating therapeutic effects of tamsulosin which has higher affinity for blocking α1A and α1D adrenoceptors in treatment of nightmare disorder. A randomized, double blind, cross-over, placebo-controlled pilot study was conducted. Patients were randomly assigned to receive Tamsulosin 0.4 mg once daily or placebo for period of four weeks. Following a 2-week wash-out period, they were crossed over to the other group and received drug or placebo for duration of 4 additional weeks. Nightmare frequency and intensity measurements were carried out using Disturbing Dreams and Nightmares Severity Index (DDNSI). Blood pressure measurements were also performed. According to per protocol analysis, mean DDNSI scores decreased following administration of tamsulosin and a statistical trend towards significance was reported (p=0.065, d=0.236). Results of intention to treat analysis showed significant difference in DDNSI scores after drug use (p=0.030, d=0.651). Additionally, DDNSI scores dropped significantly following placebo use. However, intention to treat analysis showed no statistically significant difference pre and post placebo period (0.064, d=0.040). Tamsulosin may be effective in treatment of nightmare disorder. However, further larger clinical trials are recommended to clarify the effectiveness of tamsulosin and α1 subtypes in pharmacotherapy of nightmares.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DreamsTamsulosinHumansDouble-Blind MethodPilot ProjectsQuality of LifeTreatment Outcome

Substanzen

Tamsulosin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Department of Experimental Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, Canada.
  • Iranian Scientific Society of Clinical Hypnosis, Tehran, Iran.
  • Université de Poitiers, Unité de recherche clinique centre Hospitalier Henri Laborit, CeRCA CNRS7295, Poitiers, France.

Zitieren

APA

Naderifar, N., Roohi, E., Sharifi, A., Jaafari, N., & Hashemian, F. (2024). Therapeutic Effects of Tamsulosin in Nightmare Disorder: A Randomized, Double Blind, Placebo-Controlled, Cross-Over, Pilot Study. Drug Research, 74(02), 53-59. https://doi.org/10.1055/a-2226-3604

Vancouver

Naderifar N, Roohi E, Sharifi A, Jaafari N, Hashemian F. Therapeutic Effects of Tamsulosin in Nightmare Disorder: A Randomized, Double Blind, Placebo-Controlled, Cross-Over, Pilot Study. Drug Research. 2024;74(02):53-59. doi:10.1055/a-2226-3604

BibTeX
@article{Naderifar2024,
  author = {Naderifar, Negin and Roohi, Elnaz and Sharifi, Ali and Jaafari, Nemat and Hashemian, Farshad},
  title = {Therapeutic Effects of Tamsulosin in Nightmare Disorder: A Randomized, Double Blind, Placebo-Controlled, Cross-Over, Pilot Study},
  journal = {Drug Research},
  year = {2024},
  volume = {74},
  number = {02},
  pages = {53--59},
  doi = {10.1055/a-2226-3604}
}
Kostenlos starten →